Rein Therapeutics Inc (RNTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $34.51M
Last updated: Nov 17, 2026 at 4:29 PM ET
Rein Therapeutics Inc (RNTX) Statistics
Rein Therapeutics (RNTX) has a market cap of $34.51M and an enterprise value of $33.56M. Its share count is up 235.06% from a year earlier.
Total Valuation
Enterprise value is 2.73% below the market cap, as cash exceeds debt.
| Market Cap | $34.51M |
|---|---|
| Enterprise Value | $33.56M |
| Latest price (Nov 17, 2026) | $0.36 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 71.49% over 52 weeks and trades 47.83% below its 50-day average.
| Beta (1Y) | 2.38 |
|---|---|
| 52-Week Change | -71.49% |
| 1-Month Change | -35.43% |
| 3-Month Change | -55.00% |
| 6-Month Change | -64.18% |
| 5-Year Change | -96.15% |
| 10-Year Change | -70.12% |
| Total Return (1Y) | -71.49% |
| Total Return (3Y CAGR) | -42.95% |
| Total Return (5Y CAGR) | -51.89% |
| Max Drawdown (1Y) | -81.04% |
| Max Drawdown (3Y) | -94.86% |
| Sharpe Ratio (1Y) | -1.34 |
| Correlation with SPY (1Y) | 0.36 |
| 50-Day Average | $0.69 |
| 200-Day Average | $0.99 |
| 52-Week Range | $0.28 to $2.10 |
| RSI (14 Days) | 24.5 |
| Average Volume (20 Days) | 857.63K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.57x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.57x |
|---|---|
| Quick Ratio | 6.57x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -640.11% and return on assets is -83.66% over the last 12 months.
| Return on Equity (ROE) | -640.11% |
|---|---|
| Return on Assets (ROA) | -83.66% |
| Return on Capital Employed (ROCE) | -93.68% |
| ROIC (5Y Average) | 177.56% |
Scores
RNTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Operating Income | -$50.96M |
| Pretax Income | -$50.43M |
| Net Income | -$49.72M |
| EBITDA | -$49.35M |
| EBIT | -$50.43M |
| Reported EPS (TTM) | -$1.57 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 13.07% of the $59.43M in total assets.
| Cash and Equivalents | $943.00K |
|---|---|
| Total Debt | $0 |
| Net Cash | $943.00K |
| Net Cash Per Share | $0.01 |
| Working Capital | $31.19M |
| Shareholder Equity | $7.77M |
| Book Value Per Share | $0.09 |
| Tangible Book Value | -$12.06M |
| Total Assets | $59.43M |
| Total Liabilities | $6.66M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$22.55M |
|---|---|
| FCF Per Share | -$0.26 |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
RNTX does not pay a dividend.
| Buyback Yield | -174.71% |
|---|---|
| Shareholder Yield | -174.71% |
Stock Splits
The last split was a 1-for-20 reverse split on Nov 11, 2022.
| Last Split Date | Nov 11, 2022 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About RNTX
What is RNTX's market cap?
Rein Therapeutics has a market cap of $34.51M. Its enterprise value, which adds debt and subtracts cash, is $33.56M.
How many shares of RNTX are outstanding?
Rein Therapeutics has 88.33M shares outstanding. The count is up 235.06% from a year earlier.
Does RNTX pay a dividend?
No. Rein Therapeutics does not pay a dividend.
How much debt does RNTX have?
Rein Therapeutics has $0 of total debt and $943.00K of cash and equivalents, a net cash position of $943.00K.
RNTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors